Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-07-12
2008-12-23
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07468353
ABSTRACT:
The invention describes for the first time the preclinical/cellular and clinical relevance of VIP, PACAP as well as of substances with the same biological activity as VIP and PACAP for the treatment of interstitial lung infections such as idiopathic pulmonary fibrosis, hypersensitive pneumonia or diffused panbronchiolitis. VIP and PACAP are synthesised in different areas of the central nervous system, e.g. in specific cerebral areas such as the hippocampus and the cortex, as well as in the peripheral ganglia. VIP is also released by immune cells.
REFERENCES:
patent: 3898329 (1975-08-01), Said et al.
patent: 4237046 (1980-12-01), Bodanszky
patent: 6322810 (2001-11-01), Alkan-Onyuksel et al.
patent: 1 103 270 (2001-05-01), None
patent: 01/34088 (2001-05-01), None
patent: WO 02/43746 (2002-06-01), None
patent: WO 03/045330 (2003-06-01), None
patent: WO 03/046145 (2003-06-01), None
Todate et al. “Increased Numbers of Dendritic Cells in the Bronchiolar Tissues of Diffuse Panbronchiolitis” Am. J. Resp. Crit. Care Med., 2000, 162, 148-53.
International Preliminary Examination Report for PCT/CH2004/000439, dated May 1, 2006.
Written Opinion of the International Searching Authority for PCT/CH2004/000439.
International Search Report, PCT/CH2004/000439, Mar. 15, 2005.
Keith I.M., The Role of Endogenous Lung Neuropeptides in Regulation of the Pulmonary Circulation, Physiological Research, vol. 49(5), pp. 519-537, 2000.
Pavlou T.A. et al., American Review of Respiratory Disease, vol. 14, p. A536 Suppl. S, 1993.
Iwanaga, et al., Vasoactive Intestinal Peptide VIP Protects Against Acid-Induced Acute Lung Injury in Isolated Perfused Rat Lungs, Japanese Journal of Thoracic Diseases, vol. 27(7) pp. 789-795 (Abstract Only) 1989.
Maruno, et al., VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells, American Journal of Physiology, vol. 268(6) pp. L1047-L1051, 1995.
Kawasaki, et al., The mechanisms of the relaxation induced by vasoactive intestinal peptide in the porcine coronary artery, British Journal of Pharmacology, vol. 121(5) pp. 977-985, 1997.
Platoshyn, et al., Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation, American Journal of Physiology, vol. 279(5) pp. C1540-C1549, Nov. 1, 2000.
Amin Turocy & Calvin LLP
Bradley Christina Marchetti
Mondobiotech Laboratories Anstalt
Tsang Cecilia
LandOfFree
Biologically active substance of a vasoactive intestinal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biologically active substance of a vasoactive intestinal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biologically active substance of a vasoactive intestinal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4051896